First Time in Human Study Using GSK2330672

NCT01416324 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

17

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG: placebo
DRUG: 0.1 mg GSK2330672
DRUG: 0.3 mg GSK2330672
DRUG: 1 mg GSK2330672
DRUG: 3 mg GSK2330672
DRUG: 10 mg GSK2330672
DRUG: 30 mg GSK2330672
DRUG: 60 mg GSK2330672

Sponsor

GlaxoSmithKline